Darrin M Beaupre Selected Research

tipifarnib (R115777)

6/2011	Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
1/2006	Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
8/2005	Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
6/2005	Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
2/2004	R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Darrin M Beaupre Research Topics

Disease

12	Neoplasms (Cancer) 01/2023 - 12/2003
6	Multiple Myeloma 06/2011 - 12/2003
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023 - 01/2006
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019 - 08/2015
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 08/2015 - 08/2013
2	Leukemia 01/2023 - 12/2003
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2020 - 01/2017
1	Lymphoma (Lymphomas) 01/2017
1	Hemorrhage 08/2015
1	Infections 08/2015
1	Diarrhea 08/2015
1	Thrombocytopenia (Thrombopenia) 07/2015
1	Hypertension (High Blood Pressure) 07/2015
1	Myocardial Infarction 07/2015
1	Prostatic Neoplasms (Prostate Cancer) 07/2015
1	Lymphocytosis 07/2015
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/2013
1	Nausea 05/2010
1	Cholecystitis 05/2010
1	Constipation 05/2010
1	Edema (Dropsy) 05/2010
1	Fatigue 05/2010
1	Hematologic Neoplasms (Hematological Malignancy) 08/2005

Drug/Important Bio-Agent (IBA)

7	ibrutinibIBA 01/2020 - 08/2013
5	Agammaglobulinaemia Tyrosine KinaseIBA 01/2020 - 08/2013
5	tipifarnib (R115777)IBA 06/2011 - 02/2004
3	Bortezomib (Velcade)FDA Link 06/2011 - 08/2005
3	TransferasesIBA 08/2005 - 12/2003
2	venetoclaxIBA 01/2023 - 01/2017
2	Farnesyltranstransferase (Farnesyltransferase)IBA 06/2011 - 06/2005
2	Monoclonal AntibodiesIBA 05/2010 - 01/2010
2	rilotumumabIBA 05/2010 - 01/2010
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 05/2010 - 01/2010
2	Death Domain ReceptorsIBA 01/2006 - 12/2003
1	RNA Splicing FactorsIBA 01/2023
1	Rituximab (Mabthera)FDA Link 01/2020
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 07/2015
1	AMG 208IBA 07/2015
1	motesanib diphosphateIBA 05/2010
1	Bevacizumab (Avastin)FDA Link 05/2010
1	Biomarkers (Surrogate Marker)IBA 01/2010
1	SuspensionsIBA 01/2006
1	Fibronectins (Fibronectin)IBA 01/2006
1	Docetaxel (Taxotere)FDA Link 06/2005
1	Paclitaxel (Taxol)FDA LinkGeneric 06/2005
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 02/2004
1	Interleukin-6 (Interleukin 6)IBA 12/2003

Therapy/Procedure

4	Therapeutics 01/2023 - 01/2006
2	Drug Therapy (Chemotherapy) 06/2011 - 01/2006
1	Salvage Therapy 01/2019
1	Stem Cell Transplantation 01/2019